A Case of Antithyroid Drug-Induced Agranulocytosis Pre-Covid 19 Era

Abstract
Agranulocytosis is an infrequent and serious side effect of antithyroid drugs characterized by a noticeable reduction in granulocyte and neutrophil count, it usually occurs within the first 2-3 months of treatment. There is a variety of mechanisms by which ATD can induce agranulocytosis, direct drug effects, and immunological mechanisms. We present 33 years old female attended Atbara teaching hospital who has developed agranulocytosis 2 weeks after starting ATD to treat relapsed Graves’ disease. What was unusual about this patient is that symptoms have occurred in a period less than 15 days of starting treatment and with a dose of 45 mg/day. The physician must educate the patient about the possibility of early onset of serious side effects of ATD and to seek medical advice as soon as possible
Description
Keywords
Citation
Collections